The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
 
Teresa Macarulla
No Relationships to Disclose
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck; Merck Serono; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Daniel H. Palmer
No Relationships to Disclose
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Salarius Pharmaceuticals
Honoraria - Blend Therapeutics; Novartis; Novartis; Novartis
Consulting or Advisory Role - Blend Therapeutics; Novartis; Novartis; Novartis
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson (Inst); Labceutics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); XuanZhu (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending: “Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase”. U.S. Patent No. WO 2012135800 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. US 8,703,767 B2. Washington, D.C.:U.S. Patent and Trademark Office.
Travel, Accommodations, Expenses - Clovis Oncology; Novartis; Novartis; Novartis
 
Kenneth H. Yu
No Relationships to Disclose
 
Dalila B. Sellami
Employment - Actelion (I); Novartis
Stock and Other Ownership Interests - Actelion (I); Novartis
 
Jocelyn Zhou
Employment - Novartis
 
Wu Yi
No Relationships to Disclose
 
Hildegard Boss
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Takeda
 
Eunice L Kwak
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen